A new study shows the use of novel anticoagulants to treat atrial fibrillation (AF) on an “as needed basis” guided by diligent pulse monitoring can be an effective and safe way to lower overall risk of stroke.

May 9, 2016 — New data presented at the Heart Rhythm Society's (HRS) annual meeting highlighted the long-term safety of the retrievability of the St. Jude Medical Nanostim leadless pacemaker. Two additional presentations also showed that the Nanostim leadless pacemaker is associated with reduced rates of acute and mid-term complications compared to traditional pacemakers with leads and can improve quality of life for patients.

A new study has found an increased risk of dementia in patients with atrial fibrillation (AF) that receive long-term blood thinner warfarin (Coumadin) compared to patients that use warfarin for conditions other than AF.

May 9, 2016 —St. Jude Medical announced presentation of the MultiPoint Pacing (MPP) Investigational device exemption (IDE) clinical study results during a late-breaking clinical trial session at the Heart Rhythm Society (HRS) annual meeting. The MultiPoint Pacing technology, featured on the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and the Quadra Allure MP CRT-pacemaker (CRT-P), recently received U.S. Food and Drug Administration (FDA) approval.

May 9, 2016 — A new study presented at the Heart Rhythm Society’s 37th Annual Scientific Sessions, found that among patients with heart failure, atrial fibrillation (AF) was significantly less common among African Americans and Hispanics than among non-Hispanic whites. This study indicates a strong correlation between race and ethnicity and the development of AF for patients with heart failure.

May 9, 2016 — Medtronic announced the results of several studies evaluating a novel approach to implantable cardioverter defibrillator (ICD) therapy at Heart Rhythm 2016, the Heart Rhythm Society (HRS) annual meeting. 

S-ICD, Effortless

May 9, 2016 — The mid to long-term results from the EFFORTLESS study, the largest subcutaneous implantable cardioverter-defibrillator (S-ICD) registry in the world, show the device provides reliable treatment for ventricular tachyarrhythmias. This is the first report on the fully enrolled EFFORTLESS cohort and includes real-world outcomes of almost 1,000 patients implanted with an S-ICD. Positive results showing longevity during three- and up to five-year follow-ups were presented at Heart Rhythm 2016, the Heart Rhythm Society (HRS) annual meeting.

May 9, 2016 – A new, large study shows that 95.7 percent of individual leads were successfully removed using a procedure called transvenous lead extraction (TLE). The ELECTRa (European Lead Extraction ContTRolled) Registry, hosted by the European Heart Rhythm Association (EHRA) a registered branch of the European Society of Cardiology (ESC), is the first multinational, multi-center, prospective registry of consecutive patients undergoing TLE. 

Expert Venous Management

This course takes venous education to the next level.
- Limited to 75 participants.
- Basic knowledge of venous disease required.
- Attendees will learn the advanced management of venous disease
- Attendees submit cases prior to course and best ones are selected by faculty to discuss.
- Attendees are active participants.
- Small Faculty-Attendee Ratio = Lots of faculty interaction

Atrial fibrillation patients taking warfarin are at higher risk of developing kidney failure if anticoagulation levels are not properly managed, according to a new study from researchers at the Intermountain Medical Center Heart Institute.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now